Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
73.51
+0.21 (+0.29%)
Official Closing Price
Updated: 4:15 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
32
33
Next >
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences
December 09, 2022
The company inked a deal worth $325 million and up to $3.9 billion in milestones.
Via
Investor's Business Daily
Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate
December 09, 2022
Via
Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 15 Years
December 08, 2022
Via
Benzinga
Is Gilead Sciences a Buy?
December 08, 2022
This stock has got something to offer both dividend and growth investors.
Via
The Motley Fool
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
December 08, 2022
-Clinical Data Due Next Week at ASH-
Via
Benzinga
Is Gilead Sciences Stock Still a Buy After Soaring in 2022?
December 08, 2022
Gilead faces some challenges. But there are several reasons to think the stock could keep the momentum going.
Via
The Motley Fool
Expert Ratings for Gilead Sciences
December 01, 2022
Via
Benzinga
2 Reasons This Stock Could Outperform in 2023
November 30, 2022
It would be a continuation of this year's showing.
Via
The Motley Fool
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $17,000 Today
November 23, 2022
Via
Benzinga
Gilead Sciences Unusual Options Activity
December 02, 2022
Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly...
Via
Benzinga
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
December 02, 2022
The S&P 500 is fighting for its 200-day, a critical level for the uptrend.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
December 01, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
The Top Healthcare Stocks to Buy With $100
December 01, 2022
Triple-digit growth and innovation go hand-in-hand with these companies.
Via
The Motley Fool
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
These 3 Stocks Are Rallying While the Rest of the Market Plunges
November 30, 2022
Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds.
Via
The Motley Fool
Uncertainty Grips Markets-On A Clear Day Maybe You Can See A Week Ahead
November 28, 2022
Healthcare stocks are now favored by many strategists because of their defensive nature and focus on US markets.
Via
Talk Markets
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges
November 28, 2022
Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher.
Via
Investor's Business Daily
Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures
November 28, 2022
Via
Benzinga
What Does Gilead Sciences' Debt Look Like?
November 28, 2022
Over the past three months, shares of Gilead Sciences Inc. (NASDAQ:GILD) rose by 34.80%. Before having a look at the importance of debt, let's look at how much debt Gilead Sciences has.
Via
Benzinga
Pick These 4 Stocks With Exciting Interest Coverage Ratio
November 26, 2022
Let's take a look at some of the companies that boast an impressive interest coverage ratio.
Via
Talk Markets
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
November 23, 2022
Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching.
Via
Investor's Business Daily
This Is What Whales Are Betting On Gilead Sciences
November 22, 2022
Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly...
Via
Benzinga
2 Reasons to Buy AbbVie Stock and 1 Reason to Sell
November 22, 2022
The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem.
Via
The Motley Fool
Gilead Sciences' Debt Overview
November 21, 2022
Shares of Gilead Sciences' Inc. (NASDAQ:GILD) rose by 33.62% in the past three months. Before we understand the importance of debt, let's look at how much debt Gilead Sciences' has.
Via
Benzinga
Jim Simons 'The Man Who Solved The Market' Sold 3 Healthcare Dividend Payers, But Upped Stake In This One By 153%
November 20, 2022
Jim Simons is the founder and hedge fund manager of Renaissance Technologies, which currently has a total portfolio value north of $77 billion, per Stock Circle. This hedge fund uses a quantitative...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
November 21, 2022
During Monday's session, 50 stocks hit new 52-week highs.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
November 17, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
FTX Contagion Spreads To Hong Kong Exchange, Microsoft Outlines New Harassment Policies, Netflix Subscribers Can Terminate Freeloading Account Access: Top Stories Wednesday, Nov. 16
November 16, 2022
Benzinga
Via
Benzinga
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
November 16, 2022
Via
Benzinga
Can This Company's Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval?
November 14, 2022
Learn More about Organicell Regenerative Medicine, Inc. by gaining access to the latest research report In the medical community, the popularity of regenerative medicine is reportedly soaring primarily...
Via
Benzinga
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
32
33
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.